(Q34586251)

3 August 2017

1 reference

title

Randomized clinical trials in hepatocellular carcinoma and biliary cancer (English)

1 reference

3 August 2017

main subject

hepatocellular carcinoma

1 reference

1

Robert C G Martin

1 reference

3 August 2017

William R Jarnagin

2

1 reference

3 August 2017

publication date

1 January 2002

1 reference

Surgical oncology clinics of North America

3 August 2017

published in

1 reference

3 August 2017

volume

11

1 reference

3 August 2017

issue

1

1 reference

3 August 2017

page(s)

193-205, x

1 reference

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

A randomized phase II study of acivicin and 4'deoxydoxorubicin in patients with hepatocellular carcinoma in an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Drainage is unnecessary after elective liver resection

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

A prospective randomized evaluation of a compound of tegafur and uracil as an adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: An RTOG study

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Postoperative chemoimmunotherapy for the treatment of liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Chemohormonal therapy of unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

The effect of gamma-linolenic acid, an in vitro cytostatic substance contained in evening primrose oil, on primary liver cancer. A double-blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2803%2900081-4

7 January 2021

10.1016/S1055-3207(03)00081-4

Identifiers

DOI

1 reference

3 August 2017

1 reference